Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Liling Warren"'
Autor:
Karen Lariosa-Willingham, Dmitri Leonoudakis, Florian Simon, Kendall Walker, Philippe Guillaume, Liling Warren, Jennifer Stratton
Publikováno v:
BMC Research Notes, Vol 16, Iss 1, Pp 1-7 (2023)
Abstract Objectives Animal models of skin disease are used to evaluate therapeutics to alleviate disease. One common clinical dermatological complaint is pruritus (itch), but there is a lack of standardization in the characterization of pre-clinical
Externí odkaz:
https://doaj.org/article/5c04a0c322b541439ed55470227f9595
Autor:
Ralitsa Petrova, Abhijeet R. Patil, Vivian Trinh, Kathryn E. McElroy, Minoti Bhakta, Jason Tien, David S. Wilson, Liling Warren, Jennifer R. Stratton
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-18 (2023)
Abstract Mucopolysaccharidosis type IIIB (MPS IIIB) is a rare and devastating childhood-onset lysosomal storage disease caused by complete loss of function of the lysosomal hydrolase α-N-acetylglucosaminidase. The lack of functional enzyme in MPS II
Externí odkaz:
https://doaj.org/article/efa2650a037a46579e6a5721ffce4f53
Publikováno v:
Cells, Vol 12, Iss 11, p 1489 (2023)
Single-cell RNA sequencing (scRNA-seq) is an attractive technology for researchers to gain valuable insights into the cellular processes and cell type diversity present in all tissues. The data generated by the scRNA-seq experiment are high-dimension
Externí odkaz:
https://doaj.org/article/0471c370d492442ca209c405e4ee4541
Autor:
Astrid Yeo, Li Li, Liling Warren, Jennifer Aponte, Dana Fraser, Karen King, Kelley Johansson, Allison Barnes, Colin MacPhee, Richard Davies, Stephanie Chissoe, Elizabeth Tarka, Michelle L O'Donoghue, Harvey D White, Lars Wallentin, Dawn Waterworth
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0182115 (2017)
Darapladib, a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, failed to demonstrate efficacy for the primary endpoints in two large phase III cardiovascular outcomes trials, one in stable coronary heart disease patients (STABILITY) and o
Externí odkaz:
https://doaj.org/article/0a809759d42f43029cff85dad6751c3f
Autor:
Lini N. Pandite, Neil Kaplowitz, Thomas Powles, Andreas du Bois, Hiroomi Tada, Matthew R. Nelson, Colin F. Spraggs, Ionel Mitrica, Linda P. Briley, Sandy Stinnett, Dana J. Fraser, Karen S. King, Zhengyu Xue, Liling Warren, Alan P. Graves, Chris Carpenter, Xiaojing Wang, Toby Johnson, Chun-Fang Xu
Purpose: Pazopanib is an effective treatment for advanced renal cell carcinoma and soft-tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib-treated patients. We conducted pharmacogenetic analyses to explore mechanistic in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3839491b219ef58d50509358882ee7ba
https://doi.org/10.1158/1078-0432.c.6524039.v1
https://doi.org/10.1158/1078-0432.c.6524039.v1
Autor:
Lini N. Pandite, Neil Kaplowitz, Thomas Powles, Andreas du Bois, Hiroomi Tada, Matthew R. Nelson, Colin F. Spraggs, Ionel Mitrica, Linda P. Briley, Sandy Stinnett, Dana J. Fraser, Karen S. King, Zhengyu Xue, Liling Warren, Alan P. Graves, Chris Carpenter, Xiaojing Wang, Toby Johnson, Chun-Fang Xu
Supplementary Table S1. Summary of eight pazopanib (monotherapy) clinical studies included in the discovery pharmacogenetic liver toxicity analysis Supplementary Table S2. Summary of 23 pazopanib clinical studies included in the confirmatory pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84251c105feab3d723a3f5866015ff3d
https://doi.org/10.1158/1078-0432.22458767
https://doi.org/10.1158/1078-0432.22458767
Autor:
Linda P. Briley, Lini Pandite, Dana Fraser, Karen S. King, Xiaojing Wang, Sandy Stinnett, Colin F Spraggs, Alan P. Graves, Andreas du Bois, Hiroomi Tada, Ionel Mitrica, Matthew R. Nelson, Neil Kaplowitz, Zhengyu Xue, Thomas Powles, Liling Warren, Christopher L. Carpenter, Toby Johnson, Chun-Fang Xu
Publikováno v:
Clin Cancer Res
Purpose: Pazopanib is an effective treatment for advanced renal cell carcinoma and soft-tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib-treated patients. We conducted pharmacogenetic analyses to explore mechanistic in
Autor:
Paul C. Fletcher, Kay Maltby, Kijoung Song, Karin Mogg, Louise K Hosking, Edward T. Bullmore, Duncan Richards, Mark A. Bush, Brendan P. Bradley, Pradeep J. Nathan, Hisham Ziauddeen, Dawn M. Waterworth, Mauro Zucchetto, Liling Warren, Bhopinder K. Sarai, Chris M. Dodds, Lakshmi Vasist Johnson, Sam R. Miller
Publikováno v:
Journal of Clinical Pharmacology
The mu-opioid system has a key role in hedonic and motivational processes critical to substance addiction. However, existing mu-opioid antagonists have had limited success as anti-addiction treatments. GSK1521498 is a selective and potent mu-opioid a
Autor:
Claudia Lamina, Dawn M. Waterworth, Ramachandran S. Vasan, Alan R. Sinaiko, Jorma Viikari, Alena Stančáková, Nita G. Forouhi, Leo-Pekka Lyytikäinen, Chloe Y Y Cheung, Torben Hansen, Bernhard Paulweber, Ying Wu, Christie M. Ballantyne, Jaakko Tuomilehto, Karen S.L. Lam, Jussi Paananen, James B. Meigs, Jing Hua Zhao, Francis S. Collins, Hans U. Häring, Marie-France Hivert, Joshua W. Knowles, Zari Dastani, Andrew T. Hattersley, Ele Ferrannini, Ching-Ti Liu, Sarah Buxbaum, Mika Kähönen, Peter Henneman, Aurelian Bidulescu, Michael Boehnke, Ruth J. F. Loos, Fatiha el Bouazzaoui, Ulf Smith, Tim D. Spector, Josée Dupuis, Weijia Xie, Thomas Quertermous, Robert K. Semple, Lyudmyla Kedenko, John J. Nolan, Andrew D. Morris, Anne U. Jackson, Cornelia M. van Duijn, Ko Willems van Dijk, Markku Laakso, Robert A. Scott, Na Zhu, Oluf Pedersen, Terho Lehtimäki, Claudia Langenberg, Ke Hao, Christopher J. Gillson, Olli T. Raitakari, Mark I. McCarthy, Florian Kronenberg, Jaeyoung Hong, James S. Pankow, Debbie A Lawlor, Nicholas J. Wareham, Karen L. Mohlke, Timothy M. Frayling, Tanya M. Teslovich, Sandra H. Dunn, Alessandro Doria, Cecilia M. Lindgren, Richard N. Bergman, Johanna Kuusisto, Hanieh Yaghootkar, Liling Warren, Stefan Gustafsson, Erik Ingelsson, Colin N. A. Palmer, Mark Walker, Themistocles L. Assimes, J. Brent Richards
Publikováno v:
Diabetes, 62(10), 3589-3598
Yaghootkar, H, Lamina, C, Scott, R A, Dastani, Z, Hivert, M F, Warren, L L, Stancakova, A, Buxbaum, S G, Lyytikaeinen, L P, Henneman, P, Wu, Y, Cheung, C Y Y, Pankow, J S, Jackson, A U, Gustafsson, S, Zhao, J H, Ballantyne, C M, Xie, W J, Bergman, R N, Boehnke, M, el Bouazzaoui, F, Collins, F S, Dunn, S H, Dupuis, J, Forouhi, N G, Gillson, C, Hattersley, A T, Hong, J Y, Kaehoenen, M, Kuusisto, J, Kedenko, L, Kronenberg, F, Doria, A, Assimes, T L, Ferrannini, E, Hansen, T, Hao, K, Haering, H, Knowles, J W, Lindgren, C M, Nolan, J J, Paananen, J, Pedersen, O, Quertermous, T, Smith, U, Lehtimaeki, T, Liu, C T, Loos, R J F, McCarthy, M I, Morris, A D, Vasan, R S, Spector, T D, Teslovich, T M, Tuomilehto, J, van Dijk, K W, Viikari, J S, Zhu, N, Langenberg, C, Ingelsson, E, Semple, R K, Sinaiko, A R, Palmer, C N A, Walker, M, Lam, K S L, Paulweber, B, Mohlke, K L, van Duijn, C, Raitakari, O T, Bidulescu, A, Wareham, N J, Laakso, M, Waterworth, D M, Lawlor, D A, Meigs, J B, Richards, J B, Frayling, T M, Consortium, G & Consortium, R 2013, ' Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes ', Diabetes, vol. 62, pp. 3589-3598 . https://doi.org/10.2337/db13-0128
Diabetes
Yaghootkar, H, Lamina, C, Scott, R A, Dastani, Z, Hivert, M F, Warren, L L, Stancáková, A, Buxbaum, S G, Lyytikäinen, L P, Henneman, P, Wu, Y, Cheung, C Y Y, Pankow, J S, Jackson, A U, Gustafsson, S, Zhao, J H, Ballantyne, C M, Xie, W, Bergman, R N, Boehnke, M, El Bouazzaoui, F, Collins, F S, Dunn, S H, Dupuis, J, Forouhi, N G, Gillson, C, Hattersley, A T, Hong, J, Kähönen, M, Kuusisto, J, Kedenko, L, Kronenberg, F, Doria, A, Assimes, T L, Ferrannini, E, Hansen, T, Hao, K, Häring, H, Knowles, J W, Lindgren, C M, Nolan, J J, Paananen, J, Pedersen, O, Quertermous, T, Smith, U, Lehtimäki, T, Liu, C T, Loos, R J F, McCarthy, M I, Morris, A D, Vasan, R S, Spector, T D, Teslovich, T M, Tuomilehto, J, Van Dijk, K W, Viikari, J S, Zhu, N, Langenberg, C, Ingelsson, E, Semple, R K, Sinaiko, A R, Palmer, C N A, Walker, M, Lam, K S L, Paulweber, B, Mohlke, K L, Van Duijn, C, Raitakari, O T, Bidulescu, A, Wareham, N J, Laakso, M, Waterworth, D M, Lawlor, D A, Meig, J B, Richards, J B & Frayling, T M 2013, ' Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes ', Diabetes, vol. 62, no. 10, pp. 3589-3598 . https://doi.org/10.2337/db13-0128
Diabetes, 62(10), 3589-3598. American Diabetes Association Inc.
Yaghootkar, H, Lamina, C, Scott, R A, Dastani, Z, Hivert, M F, Warren, L L, Stancakova, A, Buxbaum, S G, Lyytikaeinen, L P, Henneman, P, Wu, Y, Cheung, C Y Y, Pankow, J S, Jackson, A U, Gustafsson, S, Zhao, J H, Ballantyne, C M, Xie, W J, Bergman, R N, Boehnke, M, el Bouazzaoui, F, Collins, F S, Dunn, S H, Dupuis, J, Forouhi, N G, Gillson, C, Hattersley, A T, Hong, J Y, Kaehoenen, M, Kuusisto, J, Kedenko, L, Kronenberg, F, Doria, A, Assimes, T L, Ferrannini, E, Hansen, T, Hao, K, Haering, H, Knowles, J W, Lindgren, C M, Nolan, J J, Paananen, J, Pedersen, O, Quertermous, T, Smith, U, Lehtimaeki, T, Liu, C T, Loos, R J F, McCarthy, M I, Morris, A D, Vasan, R S, Spector, T D, Teslovich, T M, Tuomilehto, J, van Dijk, K W, Viikari, J S, Zhu, N, Langenberg, C, Ingelsson, E, Semple, R K, Sinaiko, A R, Palmer, C N A, Walker, M, Lam, K S L, Paulweber, B, Mohlke, K L, van Duijn, C, Raitakari, O T, Bidulescu, A, Wareham, N J, Laakso, M, Waterworth, D M, Lawlor, D A, Meigs, J B, Richards, J B, Frayling, T M, Consortium, G & Consortium, R 2013, ' Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes ', Diabetes, vol. 62, pp. 3589-3598 . https://doi.org/10.2337/db13-0128
Diabetes
Yaghootkar, H, Lamina, C, Scott, R A, Dastani, Z, Hivert, M F, Warren, L L, Stancáková, A, Buxbaum, S G, Lyytikäinen, L P, Henneman, P, Wu, Y, Cheung, C Y Y, Pankow, J S, Jackson, A U, Gustafsson, S, Zhao, J H, Ballantyne, C M, Xie, W, Bergman, R N, Boehnke, M, El Bouazzaoui, F, Collins, F S, Dunn, S H, Dupuis, J, Forouhi, N G, Gillson, C, Hattersley, A T, Hong, J, Kähönen, M, Kuusisto, J, Kedenko, L, Kronenberg, F, Doria, A, Assimes, T L, Ferrannini, E, Hansen, T, Hao, K, Häring, H, Knowles, J W, Lindgren, C M, Nolan, J J, Paananen, J, Pedersen, O, Quertermous, T, Smith, U, Lehtimäki, T, Liu, C T, Loos, R J F, McCarthy, M I, Morris, A D, Vasan, R S, Spector, T D, Teslovich, T M, Tuomilehto, J, Van Dijk, K W, Viikari, J S, Zhu, N, Langenberg, C, Ingelsson, E, Semple, R K, Sinaiko, A R, Palmer, C N A, Walker, M, Lam, K S L, Paulweber, B, Mohlke, K L, Van Duijn, C, Raitakari, O T, Bidulescu, A, Wareham, N J, Laakso, M, Waterworth, D M, Lawlor, D A, Meig, J B, Richards, J B & Frayling, T M 2013, ' Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes ', Diabetes, vol. 62, no. 10, pp. 3589-3598 . https://doi.org/10.2337/db13-0128
Diabetes, 62(10), 3589-3598. American Diabetes Association Inc.
Adiponectin is strongly inversely associated with insulin resistance and type 2 diabetes, but its causal role remains controversial. We used a Mendelian randomization approach to test the hypothesis that adiponectin causally influences insulin resist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f2386755cd164d07f113ab70cbd80fe
https://ora.ox.ac.uk/objects/uuid:fd376590-520a-44d4-a377-1d5ba7bc4b0c
https://ora.ox.ac.uk/objects/uuid:fd376590-520a-44d4-a377-1d5ba7bc4b0c
Autor:
Toby Johnson, Liling Warren, Dawn Waterworth, Stephanie L. Chissoe, Arlene R Hughes, Matthew R. Nelson, Chun-Fang Xu
Publikováno v:
Nature reviews. Genetics. 17(4)
Lack of sufficient efficacy is the most common cause of attrition in late-phase drug development. It has long been envisioned that genetics could drive stratified drug development by identifying those patient subgroups that are most likely to respond